Accueil   Diary - News   All news Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine

Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine

  • Tonghua Dongbao (THDB) will manufacture and supply insulin glargine and insulin lispro to Adocia worldwide, excluding China
  • These agreements expand the previously announced strategic alliance between both companies whereby THDB received licenses to develop and commercialize Adocia’s BioChaperone® Lispro and BioChaperone® Combo in China and other territories

 

ADOCIA (Euronext Paris: FR0011184241 – ADOC) and Tonghua Dongbao Pharmaceuticals (Shanghai Stock Exchange 600867) announced  an expansion of their strategic alliance with Tonghua Dongbao to manufacture and supply insulin lispro and insulin glargine APIs to Adocia worldwide, excluding China.

 

 

Read the press release